Background: On 11th March 2020, WHO announced novel coronavirus infectious (COVID-19) as a pandemic. New Coronavirus Pneumonia (NCP) that emerge on 31st December 2019 from China and quickly became a Public Health Emergency of International Concern (PHEIC). In the absence of evidence-based proven prophylactic or therapeutic options, chloroquine/hydroxychloroquine (CQ/HCQ) patented as first line choice in COVID- 19 treatment, which raised concerns about drug poisoning, especially ocular toxicity.
Objective: This study aims to investigate the possibility of ocular toxicity and the need for ophthalmic counseling to prescribing this therapeutic protocol.
Methods: All the articles that were most relevant to the COVID-19 therapeutic or prophylactic options and CQ derivative ocular toxicity, were founded by a literature search and were thoroughly reviewed.
Results: Anecdotal recent reports introduce CQ/HCQ as an effective therapeutic or prophylactic choice for COVID-19. Because of the short time prescribe and the insignificant cumulative dose of the drug on the one hand and a higher risk of cross-infection during an ophthalmic examination, on the other hand, an ophthalmologic consult is not recommended except in highrisk patients for retinal toxicity.
Conclusion: This study recommended ophthalmic evaluation before CQ/HCQ prescription for treatment or prophylaxis of COVID-19 only in preexisting maculopathy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/1574891X15999200819102507 | DOI Listing |
Visual loss following secondary retinitis pigmentosa (RP) is a rare complication of cytotoxic chemotherapy. Few cases of docetaxel- and/or platinum-induced retinal toxicity have been reported. Routine ocular examination of patients undergoing chemotherapy is required for early recognition and intervention of ocular toxicity.
View Article and Find Full Text PDFPathogens
December 2024
Laboratório de Virologia e Parasitologia Molecular, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro 21040900, RJ, Brazil.
Herpes simplex virus-1 (HSV-1) can invade the central nervous system (CNS). However, antiviral drugs used to treat HSV-1 have significant toxicity and resistance. An alternative approach involves the use of the CRISPR/Cas9 complex as a viral replication inhibitor.
View Article and Find Full Text PDFCancer Res Treat
December 2024
Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul.
Purpose: To investigate the clinical outcomes of stereotactic body radiation therapy (SBRT) in patients with large uveal melanoma (UM).
Materials And Methods: We conducted a retrospective review of 64 consecutive patients with UM treated with Cyberknife at Yonsei Cancer Center from September 2015 to October 2021. The median radiation dose was 60 Gy (range 48-64 Gy) administered in four fractions every alternate day.
Cureus
December 2024
Department of Clinical Research, Clinical Virtual Research Center, Wayne, USA.
Most of the drugs that we use in our everyday clinic cause ocular side effects or toxicity, depending on the drug duration and dose. Eye care physicians should be familiar with any possible ocular side effects linked to these medications, which could save the physicians' time to determine the diagnosis of the ocular irritation or toxicity. Not all medications are listed in this review, but we did go over the most common systemic medications based on our experience seeing patients in our everyday clinic.
View Article and Find Full Text PDFFront Immunol
January 2025
Center of Clinical Pharmacology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Introduction: Antibody-drug conjugates (ADCs) are increasingly utilized in patients with solid tumors and hematologic malignancies. However, the adverse ocular toxicity induced by ADCs has not been comprehensively evaluated in real-world clinical settings.
Methods: Data from April 2019 to March 2024 based on the FDA Adverse Event Reporting System (FAERS) were extracted and analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!